Integra Lifesciences Holdings (IART) Net Margin (2009 - 2026)

Integra Lifesciences Holdings has disclosed Net Margin across 18 years of filings, most recently posting 1.07% for Q2 2026.

• In Q2 2026, Net Margin rose 11754.0% year-over-year to 1.07%; the TTM figure through Jun 2026 stood at 0.44% (up 3043.0% YoY), while the FY2025 annual figure was 31.58%, down 3115.0% from the prior year.
• Net Margin came in at 1.07% for Q2 2026 at Integra Lifesciences Holdings, up from 1.18% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 13.3% in Q4 2022 to a low of 116.47% in Q2 2025.
• Average Net Margin over 5 years is 3.52%, with a median of 1.08% recorded in 2023.
• Year-over-year, Net Margin slumped 11351 bps in 2025 and surged 11754 bps in 2026.
• Over 5 years, Net Margin stood at 13.3% in 2022, then slumped by 62 bps to 5.0% in 2023, then retreated by 12 bps to 4.39% in 2024, then tumbled by 109 bps to 0.39% in 2025, then soared by 373 bps to 1.07% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 1.07% in Q2 2026, 1.18% in Q1 2026, and 0.39% in Q4 2025.